Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026.
Luigi La Corte will join Galderma on April 1 to begin a smooth and orderly transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026 to ensure a seamless transition before pursuing another senior executive opportunity outside the organization.
“Luigi La Corte is an accomplished financial leader with deep experience across global healthcare and consumer organizations. I am delighted to welcome him to the Executive Committee and look forward to working with him closely as we continue to execute our Integrated Dermatology Strategy and extend our category leadership in dermatology. I would also like to thank Thomas for his commitment to ensuring a seamless transition and his many contributions to Galderma during his time with the company.” FLEMMING ØRNSKOV, M.D., MPH CHIEF EXECUTIVE OFFICER GALDERMA |
Luigi La Corte brings more than 30 years of international financial leadership experience across healthcare and consumer businesses. Most recently, he served as CFO of the global pharmaceutical company Recordati S.p.A from 2019 – 2025, where he was responsible for Group Finance, Investor Relations, Sustainability and Information Systems. He was appointed to Recordati's Board of Directors in 2022, a position he continues to hold.
Previously, Luigi La Corte held a range of senior finance leadership roles within the pharmaceutical sector, including positions at GlaxoSmithKline, AstraZeneca and Alliance Unichem, and served as CFO at Pladis Food Group. Earlier in his career he also worked for Bain & Company, PepsiCo and Procter & Gamble. An Italian national, he holds a Master in Economics from Luiss University and is a Fellow of the Chartered Institute of Management Accountants.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
Forward-looking statements
Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", " believes", "expects", "anticipates", "intends", "estimates", "will", "may", "continues", "should" and similar expressions. These forward-looking statements reflect, at the time, Galderma's beliefs, intentions and current targets/ aims concerning, among other things, Galderma's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma’s markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.
BPI’s BanKo Teams Up with ACI
恭贺法兰尼净水器与著名影视明星吕一签约仪式
沾化区大高镇召开2021年春季大学生入伍座谈会
注意-更正并替换:Kioxia推出适用于云端
彪马与国际象棋世界冠军Magnus Carlsen
Magnus Carlsen和Christian
Canva和MMA Global的最新调查发现
汪登保——2019年最受人民喜爱的艺术家
雅马哈推出 Thinking About
project44扩大在中国的网络覆盖范围
锋纤往来 铁点银钩 ——论阎景山先生书法艺术
Omdia:2025年第三季度,全球开放式耳机出货量突
“森大厦teamLab数字艺术博物馆:无界”庆祝开
Zigbee + BLE 双协议融合!
数字合作组织第五届 大会闭幕
PUMA任命Indrajeet Sen为PUMA集团采购高
Kinaxis宣布达成推动能源行业供应链转型的交易
玫琳凯欧洲分公司荣获2018 Brandon Hall
乐和弥勒·慈爱人间——王玮百幅弥勒精品展在
Kioxia推出面向PC原始设备制造商
第三十五届大地之光征文“品牌·公益”论坛在
南京同仁堂与恒镁科技联手搭建健康领域会员制
雷蛇承诺投入5000万美元 支援受新冠肺炎
Improbable于2023年实现盈利